文献速递生殖医学

冻融胚胎移植体外受精/卵胞浆内单精子注射周期中黄体支持方案的比较:一项网状Meta分析

Comparison of Luteal Support Protocols in Frozen IVF/ICSI Cycles: A Network Meta-Analysis.
PubMed 文献 · BJOG · 2025-05-02

该贝叶斯网状Meta分析纳入14项研究(其中8项为随机对照试验),共4688名接受冻融胚胎移植的女性,比较12种黄体支持干预。结果显示,在阴道用黄体酮基础上加用单次或双次皮下促性腺激素释放激素激动剂(GnRHa)可显著改善临床妊娠,风险比(RR)为1.86(95%可信区间1.18至2.93)。

要点

  • 阴道用黄体酮联合单次或双次皮下GnRHa较其他方案显著改善临床妊娠,RR 1.86(95%CrI 1.18至2.93)。
  • 皮下GnRHa方案为移植后第3天单次给药,或移植后第3天和第6天双次给药,持续至第12周。
  • 纳入14项研究(8项随机对照试验),共4688名参与者,总体偏倚风险为中等,各结局网络不一致性低。

核心结论

  • 在阴道用黄体酮方案基础上加用0.1毫克皮下GnRHa,单次(移植后第3天)或双次(移植后第3天和第6天)给药并持续至第12周,似乎可改善冻融胚胎移植周期的临床妊娠。

研究设计与样本

  • 贝叶斯网状Meta分析,纳入随机对照试验和观察性研究,检索12个数据库和2个前瞻性注册库,检索时间从建库至2024年1月1日,研究前瞻性注册于PROSPERO(CRD42024513549)。
  • 共纳入14项研究,其中8项为随机对照试验,比较12种干预,涉及4688名参与者。
  • 采用随机效应模型,报告风险比(RR)及95%可信区间(CrI)。

主要发现

  • 13项研究报告了临床妊娠结局,阴道用黄体酮联合单次或双次皮下GnRHa显著改善临床妊娠,RR 1.86(95%CrI 1.18至2.93)。
  • 总体CiNeMa偏倚风险评估为中等,各结局的网络不一致性低。

关键数值与推荐

  • 阴道用黄体酮联合单次或双次皮下GnRHa方案:移植后第3天单次给药,或移植后第3天和第6天双次给药,持续至第12周。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Luteal support is a core success factor of frozen embryo transfers (FET). However, inconsistency across recommended protocols generates notable heterogeneity across reproductive outcomes. OBJECTIVE: To determine the most effective luteal support strategy (LPS) based on five key factors related to the effectiveness of FET cycles. SEARCH STRATEGY: Twelve databases and two prospective registers were searched from inception to 1st January 2024. The study was prospectively registered under the PROSPERO database (CRD42024513549). SELECTION CRITERIA: Randomised Controlled Trials (RCTs) and observational studies of women undergoing frozen embryo transfers were included. DATA COLLECTION AND ANALYSIS: Bayesian network meta-analysis (NMA) model presenting random effects, risk ratios (RRs) with 95% credibility intervals (CrIs) was employed. Primary outcomes included clinical pregnancy, live birth, and miscarriage. Secondary outcomes included biochemical pregnancy and multiple pregnancy events. MAIN RESULTS: Fourteen studies, of which eight RCTs, comparing 12 interventions upon 4688 participants, were included. Overall, CiNeMa risk of bias was moderate, and network inconsistency per outcome was low. Thirteen studies reported on clinical pregnancy events with vaginal progesterone (VP) and a single or double dose of subcutaneous GnRH agonist (GnRHa), significantly improving clinical pregnancy, RR 1.86 [95% CrI 1.18, 2.93]. CONCLUSIONS: The addition of 0.1 mg subcutaneous GnRH agonist in a single (Day 3 post ET) or double (Day 3 and Day 6 post ET) schema upon a vaginal progesterone regimen till Week 12 appears to improve clinical pregnancy events in FET cycles.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Balachandren N, Veeramani M, Suriyakumar S, et al. Comparison of Luteal Support Protocols in Frozen IVF/ICSI Cycles: A Network Meta-Analysis. BJOG. 2025. PMID: 40313195. doi:10.1111/1471-0528.18172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。